基本信息
views: 190
Career Trajectory
Bio
Emmanuelle is a French microbiologist, geneticist and biochemist. She received her education in Paris (France) and pursued a scientific career in academic research institutions in Paris, New York and Memphis (United States), Vienna (Austria), Umeå (Sweden) and Braunschweig (Germany). Emmanuelle is now based in Berlin (Germany).
Emmanuelle has devoted most of her scientific career to understanding the fundamental mechanisms of diseases, with a particular interest in infections caused by Gram-positive pathogenic bacteria such as Listeria, staphylococci and streptococci.
Emmanuelle is best known for her and her lab’s research on the CRISPR-Cas9 adaptive immune system in the human pathogen Streptococcus pyogenes and other bacterial species, which laid the foundation for the development of a highly versatile and specific genome editing and engineering technology. The technology known as CRISPR-Cas is revolutionizing research in the life sciences. CRISPR-Cas has opened up entirely new possibilities in biotechnology and biomedical gene therapies that have an impact on society and humanity. The field of CRISPR-Cas biology and engineering continues to grow at a rapid pace, with exciting new developments emerging almost weekly.
For her and her team’s contribution to the discovery of CRISPR-Cas9, Emmanuelle has received numerous honors, decorations, prizes, awards and honorary doctorates in Europe, Asia and North America. She is an elected member of national and international scientific academies.
Emmanuelle is the inventor and co-owner of the core intellectual property of the CRISPR-Cas9 technology. Together with Rodger Novak and Shaun Foy, she co-founded CRISPR Therapeutics and ERS Genomics to develop the CRISPR-Cas genome engineering technology for biotechnology and biomedical applications.
Emmanuelle has devoted most of her scientific career to understanding the fundamental mechanisms of diseases, with a particular interest in infections caused by Gram-positive pathogenic bacteria such as Listeria, staphylococci and streptococci.
Emmanuelle is best known for her and her lab’s research on the CRISPR-Cas9 adaptive immune system in the human pathogen Streptococcus pyogenes and other bacterial species, which laid the foundation for the development of a highly versatile and specific genome editing and engineering technology. The technology known as CRISPR-Cas is revolutionizing research in the life sciences. CRISPR-Cas has opened up entirely new possibilities in biotechnology and biomedical gene therapies that have an impact on society and humanity. The field of CRISPR-Cas biology and engineering continues to grow at a rapid pace, with exciting new developments emerging almost weekly.
For her and her team’s contribution to the discovery of CRISPR-Cas9, Emmanuelle has received numerous honors, decorations, prizes, awards and honorary doctorates in Europe, Asia and North America. She is an elected member of national and international scientific academies.
Emmanuelle is the inventor and co-owner of the core intellectual property of the CRISPR-Cas9 technology. Together with Rodger Novak and Shaun Foy, she co-founded CRISPR Therapeutics and ERS Genomics to develop the CRISPR-Cas genome engineering technology for biotechnology and biomedical applications.
Research Interests
Papers共 38 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Communications biologyno. 1 (2023): 1005-13
Methods in molecular biology (Clifton, N.J.) (2023): 151-165
Florian D Fabiani,Thibaud T Renault, Britta Peters,Tobias Dietsche,Eric J C Gálvez,Alina Guse, Karen Freier,Emmanuelle Charpentier,Till Strowig,Mirita Franz-Wachtel,Boris Macek,Samuel Wagner,
Load More
Author Statistics
#Papers: 38
#Citation: 11510
H-Index: 23
G-Index: 32
Sociability: 5
Diversity: 3
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn